{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T19:54:56Z","timestamp":1787860496482,"version":"build-2784847793"},"reference-count":74,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Anaesthesiology"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.bpa.2018.06.007","type":"journal-article","created":{"date-parts":[[2018,7,2]],"date-time":"2018-07-02T21:22:17Z","timestamp":1530566537000},"page":"149-164","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":68,"title":["New benzodiazepines for sedation"],"prefix":"10.1016","volume":"32","author":[{"given":"Elyse M.","family":"Cornett","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew B.","family":"Novitch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Brunk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly S.","family":"Davidson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bethany L.","family":"Menard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard D.","family":"Urman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan D.","family":"Kaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bpa.2018.06.007_bib1","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1111\/j.1399-6576.1982.tb01817.x","article-title":"Intravenous benzodiazepines as anaesthetic agents: pharmacokinetics and clinical consequences","volume":"26","author":"Kanto","year":"1982","journal-title":"Acta Anaesthesiol Scand"},{"key":"10.1016\/j.bpa.2018.06.007_bib2","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.pmedr.2017.12.010","article-title":"Outpatient, combined use of opioid and benzodiazepine medications in the United States, 1993-2014","volume":"9","author":"Hirschtritt","year":"2018","journal-title":"Prev Med Reports"},{"key":"10.1016\/j.bpa.2018.06.007_bib3","series-title":"Overdose death rates | national institute on drug abuse (NIDA)","year":"2017"},{"key":"10.1016\/j.bpa.2018.06.007_bib4","first-page":"420","article-title":"Concurrent use of opioids and benzodiazepines: evaluation of prescription drug\u00a0monitoring by a United States laboratory","volume":"11","author":"McClure","year":"2017","journal-title":"J\u00a0Addict Med"},{"key":"10.1016\/j.bpa.2018.06.007_bib5","first-page":"249","article-title":"Co-prescription of opioids with benzodiazepine and other co-medications among opioid users: differential in opioid doses","volume":"10","author":"Zin","year":"2017","journal-title":"J\u00a0Pain Res"},{"key":"10.1016\/j.bpa.2018.06.007_bib6","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1097\/MLR.0b013e31824ebd81","article-title":"Doctor and pharmacy shopping for controlled substances","volume":"50","author":"Peirce","year":"2012","journal-title":"Med Care"},{"key":"10.1016\/j.bpa.2018.06.007_bib7","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/dta.2211","article-title":"The emergence of new psychoactive substance (NPS) benzodiazepines: a review","volume":"10","author":"Manchester","year":"2018","journal-title":"Drug Test Anal"},{"key":"10.1016\/j.bpa.2018.06.007_bib8","doi-asserted-by":"crossref","first-page":"4107","DOI":"10.1007\/s00216-013-6798-0","article-title":"Liquid chromatography\/time-of-flight mass spectrometry analysis of postmortem blood samples for targeted toxicological screening","volume":"405","author":"Roman","year":"2013","journal-title":"Anal Bioanal Chem"},{"key":"10.1016\/j.bpa.2018.06.007_bib9","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/BF01296920","article-title":"Diazepam absorption","volume":"27","author":"Ochs","year":"1982","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.bpa.2018.06.007_bib10","doi-asserted-by":"crossref","first-page":"72","DOI":"10.2165\/00003088-197803010-00005","article-title":"Clinical pharmacokinetics of diazepam","volume":"3","author":"Mandelli","year":"1978","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.bpa.2018.06.007_bib11","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/j.1552-4604.1986.tb02919.x","article-title":"Temporal variation in triazolam pharmacokinetics and pharmacodynamics after oral administration","volume":"26","author":"Smith","year":"1986","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.bpa.2018.06.007_bib12","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/BF00563121","article-title":"Pharmacokinetics of prazepam in man","volume":"16","author":"Smith","year":"1979","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.bpa.2018.06.007_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s004140050100","article-title":"A\u00a0preliminary study on the stability of benzodiazepines in blood and plasma stored at 4 degrees C","volume":"111","author":"Skopp","year":"1998","journal-title":"Int J Leg Med"},{"key":"10.1016\/j.bpa.2018.06.007_bib14","doi-asserted-by":"crossref","first-page":"16081J","DOI":"10.1520\/JFS16081J","article-title":"Stability of nitrobenzodiazepines in postmortem blood","volume":"43","author":"Robertson","year":"1998","journal-title":"J\u00a0Forensic Sci"},{"key":"10.1016\/j.bpa.2018.06.007_bib15","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/0378-4347(85)80105-5","article-title":"Plasma determination of 3-methylclonazepam by capillary gas chromatography","volume":"338","author":"Coassolo","year":"1985","journal-title":"J\u00a0Chromatogr B Biomed Sci Appl"},{"key":"10.1016\/j.bpa.2018.06.007_bib16","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1365-2125.1981.tb01833.x","article-title":"Benzodiazepines: a summary of pharmacokinetic properties","volume":"11","author":"Greenblatt","year":"1981","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.bpa.2018.06.007_bib17","unstructured":"Manchikanti L, Christo PJ, Trescot A, et al. American society of interventional pain physicians. Pain medicine & interventional pain management: a comprehensive review\u202f: clinical aspects. n.d., http:\/\/painphysicianjournal.com\/2012\/july\/2012;%2015;S67\u2013S116.pdf."},{"key":"10.1016\/j.bpa.2018.06.007_bib18","doi-asserted-by":"crossref","first-page":"11S","DOI":"10.1111\/j.1365-2125.1983.tb02266.x","article-title":"Chemical structure and properties of midazolam compared with other benzodiazepines","volume":"16","author":"Gerecke","year":"1983","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.bpa.2018.06.007_bib19","first-page":"214","article-title":"Benzodiazepine pharmacology and central nervous system-mediated effects","volume":"13","author":"Griffin","year":"2013","journal-title":"Ochsner J"},{"key":"10.1016\/j.bpa.2018.06.007_bib20","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/sj.bjp.0704459","article-title":"Role of the histidine residue at position 105 in the human alpha 5 containing GABA(A) receptor on the affinity and efficacy of benzodiazepine site ligands","volume":"135","author":"Kelly","year":"2002","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.bpa.2018.06.007_bib21","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/S0026-895X(24)12233-X","article-title":"Molecular targets for the myorelaxant action of diazepam","volume":"59","author":"Crestani","year":"2001","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.bpa.2018.06.007_bib22","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1016\/j.clinthera.2009.12.015","article-title":"A\u00a0review of the clinical pharmacokinetics of opioids, benzodiazepines, and antimigraine drugs delivered intranasally","volume":"31","author":"Veldhorst-Janssen","year":"2009","journal-title":"Clin Therapeut"},{"key":"10.1016\/j.bpa.2018.06.007_bib23","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S0950-3501(05)80046-7","article-title":"Pharmacokinetics of benzodiazepines and their antagonists","volume":"5","author":"Nilsson","year":"1991","journal-title":"Baillieres Clin Anaesthesiol"},{"key":"10.1016\/j.bpa.2018.06.007_bib24","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1002\/phar.1806","article-title":"Remimazolam: pharmacologic considerations and clinical role in anesthesiology","volume":"36","author":"Wesolowski","year":"2016","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.bpa.2018.06.007_bib25","first-page":"00166","article-title":"Remimazolam: a new ultra short acting benzodiazepine","volume":"4","author":"Whizar-Lugo","year":"2016","journal-title":"J\u00a0Anesth Crit Care Open Access"},{"key":"10.1016\/j.bpa.2018.06.007_bib26","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1213\/ANE.0000000000000548","article-title":"A\u00a0PhaseIIa, randomized, double-blind study of remimazolam (CNS 7056) versus midazolam for sedation in upper gastrointestinal endoscopy","volume":"120","author":"Borkett","year":"2015","journal-title":"Anesth Analg"},{"key":"10.1016\/j.bpa.2018.06.007_bib27","doi-asserted-by":"crossref","first-page":"388","DOI":"10.4103\/1658-354X.136627","article-title":"Remimazolam: the future of its sedative potential","volume":"8","author":"Goudra","year":"2014","journal-title":"Saudi J Anaesth"},{"key":"10.1016\/j.bpa.2018.06.007_bib28","series-title":"Tolerance to benzodiazepines. Drug depend emot behav neurophysiol neurochem approaches","first-page":"468","author":"Garibova","year":"1986"},{"key":"10.1016\/j.bpa.2018.06.007_bib31","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1093\/cvr\/cvt079","article-title":"Cardioprotection by the TSPO ligand 4\u2019-chlorodiazepam is associated with inhibition of mitochondrial accumulation of cholesterol at reperfusion","volume":"98","author":"Paradis","year":"2013","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.bpa.2018.06.007_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1478-811X-11-13","article-title":"The 1, 4-benzodiazepine Ro5-4864 (4-chlorodiazepam) suppresses multiple pro-inflammatory mast cell effector functions","volume":"11","author":"Yousefi","year":"2013","journal-title":"Cell Commun Signal"},{"key":"10.1016\/j.bpa.2018.06.007_bib33","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1128\/AAC.38.4.812","article-title":"Effect of peripheral benzodiazepine receptor ligands on lipopolysaccharide-induced tumor necrosis factor activity in thioglycolate-treated mice","volume":"38","author":"Matsumoto","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bpa.2018.06.007_bib34","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s002130050189","article-title":"The pharmacokinetics and pharmacodynamics of adinazolam: multi-ethnic comparisons","volume":"129","author":"Ajir","year":"1997","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.bpa.2018.06.007_bib35","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1177\/0091270004269105","article-title":"Kinetics and dynamics of intravenous adinazolam, N-desmethyl adinazolam, and alprazolam in healthy volunteers","volume":"45","author":"Venkatakrishnan","year":"2005","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.bpa.2018.06.007_bib36","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0028-3908(92)90157-K","article-title":"Effects of adinazolam on plasma-catecholamine, heart-rate and blood-pressure responses in stressed and nonstressed rats","volume":"31","author":"Krieman","year":"1992","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bpa.2018.06.007_bib37","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/0304-3940(84)90514-7","article-title":"Benzodiazepine interactions with GABA receptors","volume":"47","author":"Haefely","year":"1984","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.bpa.2018.06.007_bib38","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/S0022-3565(25)24414-7","article-title":"Benzodiazepines, but not beta carbolines, limit high frequency repetitive firing of action potentials of spinal cord neurons in cell culture","volume":"244","author":"McLean","year":"1988","journal-title":"J\u00a0Pharmacol Exp Therapeut"},{"key":"10.1016\/j.bpa.2018.06.007_bib39","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jpba.2018.02.032","article-title":"In\u00a0vitro Phase I and Phase II metabolism of the new designer benzodiazepine cloniprazepam using liquid chromatography coupled to quadrupole time-of-flight mass spectrometry","volume":"153","author":"Mortel\u00e9","year":"2018","journal-title":"J\u00a0Pharmaceut Biomed Anal"},{"key":"10.1016\/j.bpa.2018.06.007_bib40","doi-asserted-by":"crossref","DOI":"10.1002\/dta.2387","article-title":"Experimental versus theoretical log D 7.4, pK a and plasma protein binding values for benzodiazepines appearing as new psychoactive substances","author":"Manchester","year":"2018","journal-title":"Drug Test Anal"},{"key":"10.1016\/j.bpa.2018.06.007_bib41","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0378-4347(00)84153-5","article-title":"Rapid quantitation of flurazepam and its major metabolite, N-desalkylflurazepam, in human plasma by gas\u2014liquid chromatography with electron-capture detection","volume":"222","author":"Riva","year":"1981","journal-title":"J\u00a0Chromatogr B Biomed Sci Appl"},{"key":"10.1016\/j.bpa.2018.06.007_bib42","unstructured":"The UN Drug control conventions | Transnational institute n.d., https:\/\/www.tni.org\/files\/publication-downloads\/primer_unconventions_24102015.pdf."},{"key":"10.1016\/j.bpa.2018.06.007_bib43","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s00414-017-1541-6","article-title":"Characterization and identification of eight designer benzodiazepine metabolites by incubation with human liver microsomes and analysis by a triple quadrupole mass spectrometer","volume":"131","author":"El Balkhi","year":"2017","journal-title":"Int J Leg Med"},{"key":"10.1016\/j.bpa.2018.06.007_bib44","doi-asserted-by":"crossref","first-page":"827","DOI":"10.2174\/138920008786049258","article-title":"Benzodiazepine metabolism: an analytical perspective","volume":"9","author":"Mandrioli","year":"2008","journal-title":"Curr Drug Metabol"},{"key":"10.1016\/j.bpa.2018.06.007_bib45","unstructured":"Psychoactive substances act 2016 [n.d]., http:\/\/www.legislation.gov.uk\/ukpga\/2016\/2\/contents\/enacted."},{"key":"10.1016\/j.bpa.2018.06.007_bib47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11419-016-0338-5","article-title":"Metabolites replace the parent drug in the drug arena. The cases of fonazepam and nifoxipam","volume":"35","author":"Katselou","year":"2017","journal-title":"Forensic Toxicol"},{"key":"10.1016\/j.bpa.2018.06.007_bib48","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1002\/dta.1628","article-title":"Characterization of the designer benzodiazepine diclazepam and preliminary data on its metabolism and pharmacokinetics","volume":"6","author":"Moosmann","year":"2014","journal-title":"Drug Test Anal"},{"key":"10.1016\/j.bpa.2018.06.007_bib49","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1093\/jat\/bkv122","article-title":"ELISA detection of phenazepam, etizolam, pyrazolam, flubromazepam, diclazepam and delorazepam in blood using immunalysis \u00ae benzodiazepine kit","volume":"40","author":"O'Connor","year":"2016","journal-title":"J\u00a0Anal Toxicol"},{"key":"10.1016\/j.bpa.2018.06.007_bib50","unstructured":"Etizolam (INN) pre-review report n.d., http:\/\/www.who.int\/medicines\/access\/controlled-substances\/5.7_Etizolam_PreRev.pdf."},{"key":"10.1016\/j.bpa.2018.06.007_bib51","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1016\/j.clinthera.2009.12.010","article-title":"Effects of treatment with etizolam 0.5 mg BID on cognitive performance: a 3-week, multicenter, randomized, double-blind, placebo-controlled, two-treatment, three-period, noninferiority crossover study in patients with anxiety disorder","volume":"31","author":"De Candia","year":"2009","journal-title":"Clin Therapeut"},{"key":"10.1016\/j.bpa.2018.06.007_bib52","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1185\/03007999009111650","article-title":"Etizolam in the treatment of generalized anxiety disorder: a double-blind study versus placebo","volume":"12","author":"Casacchia","year":"1990","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.bpa.2018.06.007_bib53","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ejphar.2005.06.047","article-title":"Low tolerance and dependence liabilities of etizolam: molecular, functional, and pharmacological correlates","volume":"519","author":"Sanna","year":"2005","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.bpa.2018.06.007_bib54","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/BF00280074","article-title":"Single and multiple dose pharmacokinetics of etizolam in healthy subjects","volume":"40","author":"Fracasso","year":"1991","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.bpa.2018.06.007_bib55","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1007\/s00228-005-0032-8","article-title":"Pharmacokinetics and pharmacodynamics of etizolam are influenced by polymorphic CYP2C19 activity","volume":"61","author":"Fukasawa","year":"2005","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.bpa.2018.06.007_bib56","doi-asserted-by":"crossref","first-page":"3788","DOI":"10.1021\/jo01058a010","article-title":"Quinazolines and 1,4-benzodiazepines. VI. Halo-, methyl-, and methoxy-substituted 1,3-Dihydro-5-phenyl-2H-1,4-benzodiazepin-2-ones","volume":"27","author":"Sternbach","year":"1962","journal-title":"J\u00a0Org Chem"},{"key":"10.1016\/j.bpa.2018.06.007_bib57","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/wps.20236","article-title":"Designer benzodiazepines: a new challenge","volume":"14","author":"Moosmann","year":"2015","journal-title":"World Psychiatr"},{"key":"10.1016\/j.bpa.2018.06.007_bib58","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1002\/jms.3279","article-title":"Detection and identification of the designer benzodiazepine flubromazepam and preliminary data on its metabolism and pharmacokinetics","volume":"48","author":"Moosmann","year":"2013","journal-title":"J\u00a0Mass Spectrom"},{"key":"10.1016\/j.bpa.2018.06.007_bib59","doi-asserted-by":"crossref","first-page":"66","DOI":"10.3109\/15563650.2015.1112907","article-title":"Flubromazolam \u2013 a new life-threatening designer benzodiazepine","volume":"54","author":"\u0141ukasik-G\u0142\u0119bocka","year":"2016","journal-title":"Clin Toxicol"},{"key":"10.1016\/j.bpa.2018.06.007_bib60","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/dta.2203","article-title":"Flubromazolam - basic pharmacokinetic evaluation of a highly potent designer benzodiazepine","volume":"10","author":"Huppertz","year":"2018","journal-title":"Drug Test Anal"},{"key":"10.1016\/j.bpa.2018.06.007_bib61","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1002\/dta.2146","article-title":"In\u00a0vitro studies on flubromazolam metabolism and detection of its metabolites in authentic forensic samples","volume":"9","author":"Noble","year":"2017","journal-title":"Drug Test Anal"},{"key":"10.1016\/j.bpa.2018.06.007_bib62","doi-asserted-by":"crossref","DOI":"10.1093\/jat\/bky012","article-title":"Characterization of flunitrazolam, a new designer benzodiazepine, in oral fluid after a controlled single administration","author":"Ameline","year":"2018","journal-title":"J\u00a0Anal Toxicol"},{"key":"10.1016\/j.bpa.2018.06.007_bib65","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1254\/fpj.74.959","article-title":"Psychopharmacological effects of flutazolam (MS-4101) (author's transl)","volume":"74","author":"Mitsushima","year":"1978","journal-title":"Nihon Yakurigaku Zasshi"},{"key":"10.1016\/j.bpa.2018.06.007_bib66","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1248\/yakushi1947.107.10_830","article-title":"The behavior of 1,4-benzodiazepine drugs in acidic media. IX. Effect of hydrolyzate of flutazolam on the central nervous system","volume":"107","author":"Yashiro","year":"1987","journal-title":"Yakugaku Zasshi"},{"key":"10.1016\/j.bpa.2018.06.007_bib67","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/dta.2003","article-title":"Detectability of designer benzodiazepines in CEDIA, EMIT II Plus, HEIA, and KIMS II immunochemical screening assays","volume":"9","author":"Pettersson Bergstrand","year":"2017","journal-title":"Drug Test Anal"},{"key":"10.1016\/j.bpa.2018.06.007_bib68","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1111\/j.1747-0285.2012.01354.x","article-title":"Synthesis, biological evaluation, and structure-activity relationship of clonazepam, meclonazepam, and 1,4-benzodiazepine compounds with schistosomicidal activity","volume":"79","author":"Menezes","year":"2012","journal-title":"Chem Biol Drug Des"},{"key":"10.1016\/j.bpa.2018.06.007_bib69","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/BF00547377","article-title":"European journal of clinical pharmacology central effects in man of the novel schistosomicidal benzodiazepine meclonazepam","volume":"29","author":"O boyle","year":"1985","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.bpa.2018.06.007_bib70","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1007\/BF00431795","article-title":"Initial study of methylelonazepam in generalized anxiety disorder Evidence for greater power in the cross-over design","volume":"87","author":"Ansseau","year":"1985","journal-title":"Psychopharmacol (Berl) nd"},{"key":"10.1016\/j.bpa.2018.06.007_bib71","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1002\/dta.2099","article-title":"Detection of the designer benzodiazepine metizolam in urine and preliminary data on its metabolism","volume":"9","author":"Kintz","year":"2017","journal-title":"Drug Test Anal"},{"key":"10.1016\/j.bpa.2018.06.007_bib72","doi-asserted-by":"crossref","DOI":"10.1002\/jms.3840","article-title":"Characterization and in\u00a0vitro phase I microsomal metabolism of designer benzodiazepines \u2014 an update comprising adinazolam, cloniprazepam, fonazepam, 3-hydroxyphenazepam, metizolam and nitrazolam","author":"Moosmann","year":"2016","journal-title":"J\u00a0Mass Spectrom"},{"key":"10.1016\/j.bpa.2018.06.007_bib73","unstructured":"TripSit factsheets - nitrazolam n.d., http:\/\/drugs.tripsit.me\/nitrazolam."},{"key":"10.1016\/j.bpa.2018.06.007_bib74","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.jflm.2011.12.014","article-title":"Phenazepam: the drug that came in from the cold","volume":"19","author":"Maskell","year":"2014","journal-title":"J\u00a0Forensic Leg Med"},{"key":"10.1016\/j.bpa.2018.06.007_bib75","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s11419-013-0187-4","article-title":"Characterization of the designer benzodiazepine pyrazolam and its detectability in human serum and urine","volume":"31","author":"Moosmann","year":"2013","journal-title":"Forensic Toxicol"},{"key":"10.1016\/j.bpa.2018.06.007_bib76","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1002\/dta.2243","article-title":"Human urinary metabolic patterns of the designer benzodiazepines flubromazolam and pyrazolam studied by liquid chromatography-high resolution mass spectrometry","volume":"10","author":"Pettersson Bergstrand","year":"2018","journal-title":"Drug Test Anal"},{"key":"10.1016\/j.bpa.2018.06.007_bib77","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s40268-017-0207-7","article-title":"Benzodiazepines and Z-drugs: an updated review of major adverse outcomes reported on in epidemiologic research","author":"Brandt","year":"2017","journal-title":"Drugs R"},{"key":"10.1016\/j.bpa.2018.06.007_bib78","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1093\/aje\/kwt327","article-title":"Trends in alcohol and other drugs detected in fatally injured drivers in the United States, 1999\u20132010","volume":"179","author":"Brady","year":"2014","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.bpa.2018.06.007_bib79","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1056\/NEJMp1713159","article-title":"Controlling the swing of the opioid pendulum","volume":"378","author":"Comerci","year":"2018","journal-title":"N\u00a0Engl J Med"}],"container-title":["Best Practice & Research Clinical Anaesthesiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521689618300545?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521689618300545?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T03:37:35Z","timestamp":1776397055000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521689618300545"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":74,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["S1521689618300545"],"URL":"https:\/\/doi.org\/10.1016\/j.bpa.2018.06.007","relation":{},"ISSN":["1753-3740"],"issn-type":[{"value":"1753-3740","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New benzodiazepines for sedation","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Anaesthesiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bpa.2018.06.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}